Replimune Insider Sale: Timing, FDA Review, and Investor Insights
Replimune’s 6,500‑share Rule 10b5‑1 sale by its COO is routine, but the move comes just before its FDA review of RP1, a potential game‑changer for oncology investors. Read how insider activity and regulatory milestones could shape the company’s futu…
4 minutes to read